Richard Denison, Ph.D., is a Lead Senior Scientist. Rachel Shaffer is a research assistant.
[UPDATE 6/24/14: Perhaps in response to this post of last week, an updated agenda for this week’s IRIS meeting was posted by EPA today that reflects a somewhat more balanced set of speakers. Industry interests appear to have consolidated their number of slots, down from a high of 8 to a high of 6 per issue, and down from a high of 6 to a high of 4 individuals per issue from the same consulting firm. In addition, several additional slots are assigned to non-industry speakers. If you wish to see the changes, here is the agenda we linked to that was current as of last week, and here’s the updated agenda posted today.]
In comments EDF made at a November 2012 stakeholder meeting held by EPA’s Integrated Risk Information System (IRIS) program, we warned that the tendency of the IRIS program to respond to criticism by expanding opportunities for “public” input would serve to increase rather than decrease the imbalance in stakeholder input.
We noted that providing more opportunities for participation not only lengthens the timeline for completing assessments; it also virtually ensures the input received by EPA is imbalanced and badly skewed toward the regulated community. That’s because companies that produce and use each chemical to be assessed – and the trade associations and myriad hired consultants that represent them – have a clear vested financial interest in the outcome of the assessment. They can and will take advantage of each and every opportunity for input, and they will be better represented than other stakeholders each and every time.
IRIS recently began holding bimonthly meetings focused on “key science issues” relating to upcoming assessments. And guess what? An army of industry representatives, including staff for trade associations and paid consultants, are overwhelming the agendas.
Exhibit A: Have a quick look at the list of speakers in the agenda for this month’s bimonthly meeting. A striking imbalance, no? As many as 8 industry representatives are set to speak on a given issue, including 6 from the same consulting firm! [UPDATE 6/24/14: See the top of this post for a description of the updated, slightly more balanced agenda; here is the agenda we had linked to that was current as of last week, and here’s the updated agenda posted today.] Read More »
As we highlighted in a previous post, EDF filed extensive comments on EPA’s draft risk evaluation for 1,4-dioxane. Among the many concerns we raised was a decision by the Trump EPA to completely dismiss female mouse liver cancer data used by EPA’s Integrated Risk Information System (IRIS) program as key inputs to its cancer risk modeling conducted in 2013. The Agency appears to be trying every trick in the trade – such as excluding most exposure sources and routes – in its effort to conclude that the chemical presents few or no risks to human health or the environment. Read on for more on this latest one. Read More